Recently, Rajan et al. 21 have shown that cixutumumab, a fully human IgG1 monoclonal antibody that targets insulin-like growth factor 1 receptor and is used as a mono-therapy, is well tolerated and is active in patients with relapsed thymoma but not in those with thymic carcinoma. This evidence concerns the gene IGF1R and thymic carcinoma.